Biotechnology

LSBF and University of Roehampton Expand Healthcare Education with LSBF Singapore Campus's New School of Health Sciences

SINGAPORE, July 22, 2026 /PRNewswire/ -- London School of Business & Finance (LSBF) Singapore Campus has announced the launch of its School of Health Sciences in 2026, marking a significant milestone in the institution's continued expansion into high-growth industries. Developed in partnership wi...

2026-07-22 15:36 4427

Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026

As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health. SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene ...

2026-07-22 11:59 3057

NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore

New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care SINGAPORE, July 22, 2026 /PRNewswire/ -- The NSG Bio Tomorrow initiative aims at supporting emerging life sciences startups working on complex challenges in...

2026-07-22 08:00 1958

Angel Yeast's Initiative Advances Internationally Recognized Codex Standard for baker's yeast

YICHANG, China, July 21, 2026 /PRNewswire/ -- The 49th session of the Codex Alimentarius Commission (CAC49), held in Geneva, Switzerland, from July 6 to 10, 2026, adopted a number of international food standards, including the Codex Standard for Baker's Yeast, which was proposed by China.

2026-07-21 20:57 2025

The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?

T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-...

2026-07-21 20:30 2747

Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia

SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of...

2026-07-21 19:00 2433

Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations

* The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] * Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against deng...

2026-07-21 16:41 3194

Haier Biomedical Presents Digital Blood Management Platform at ISBT Congress 2026, Advancing Its Transition from Equipment Provider to Full-Process Solution Partner

Driving Digital Transformation in Blood Management for Plasma Collection Centers, Hospitals, and Blood Bank Centers KUALA LUMPUR, Malaysia, July 21, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) participated at the ISBT Congress 2026 in Kuala Lumpur, present...

2026-07-21 14:29 3315

Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...

2026-07-21 12:00 2235

ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...

2026-07-21 11:50 2577

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...

2026-07-21 06:52 4951

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

•  First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). •  LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire...

2026-07-21 05:00 2933

Generative Bionics Introduces Gene.01, a Fully Functional Smart-Skin Humanoid Robot Platform Designed for Safe Human Collaboration

Built in six months, Gene.01 senses touch, proximity, force, and temperature, and it is released with its open-sourced robot model that gives Physical AI developers a shared starting point to build industrial applications Key Highlights * Fastest-ever transition to a functional humanoid: Gene....

2026-07-20 20:00 3792

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

* DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 * Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...

2026-07-20 16:20 2998

Medtrum Advances 300U Tubeless Patch Pump Toward German Launch

Higher-capacity option expands the TouchCare Nano System and supports Medtrum's continued growth in Europe BERLIN, July 20, 2026 /PRNewswire/ -- Medtrum, a global diabetes technology company, today announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, fo...

2026-07-20 15:05 1828

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-20 15:00 2471

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...

2026-07-20 13:47 1929

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combi...

2026-07-20 13:32 2570

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...

2026-07-20 12:52 2424

Neuronata-R retains conditional approval in South Korea

South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea w...

2026-07-20 07:00 2055
12345678 ... 352

Week's Top Stories